Deferred Tax Assets, Valuation Allowance of Denali Therapeutics Inc. from 31 Dec 2017 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Denali Therapeutics Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2017 to 31 Dec 2025.
  • Denali Therapeutics Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $630,806,000, a 29% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Denali Therapeutics Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $630,806,000 +$143,092,000 +29% 31 Dec 2025 10-K 26 Feb 2026 2025 FY
Q4 2024 $487,714,000 +$111,919,000 +30% 31 Dec 2024 10-K 26 Feb 2026 2025 FY
Q4 2023 $375,795,000 +$43,215,000 +13% 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q4 2022 $332,580,000 +$103,994,000 +45% 31 Dec 2022 10-K 28 Feb 2024 2023 FY
Q4 2021 $228,586,000 +$95,532,000 +72% 31 Dec 2021 10-K 27 Feb 2023 2022 FY
Q4 2020 $133,054,000 +$20,341,000 +18% 31 Dec 2020 10-K 28 Feb 2022 2021 FY
Q4 2019 $112,713,000 +$51,798,000 +85% 31 Dec 2019 10-K 26 Feb 2021 2020 FY
Q4 2018 $60,915,000 +$6,265,000 +11% 31 Dec 2018 10-K 27 Feb 2020 2019 FY
Q4 2017 $54,650,000 31 Dec 2017 10-K 12 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.